At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Study of Cryoballoon Pulmonary Vein Isolation Ablation for Patients with Symptomatic Paroxysmal Atrial Fibrillation

Clinical Trial Title: 
CRYOWM: Feasibility and safety of cryoballoon pulmonary vein isolation ablation for patients with symptomatic paroxysmal atrial fibrillation after implantation of a left atrial appendage occlusion device.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Henry D. Huang, MD
Clinical Trial Protocol Description: 

The goal of the CRYOWM study is to check the safety and efficacy of cryoballoon ablation pulmonary vein isolation treatment in patients who received left atrial appendage occlusion (Watchman) device and has symptomatic paroxysmal atrial fibrillation which is refractory to antiarrhythmic medications. Information will be collected from patients’ medical, procedural and examination records. We are expecting to recruit approximately 10 patients.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are 18 years of age or older.
  • Have had a left atrial appendage occlusion device (Watchman) implanted 3 months prior to consent.
  • Have documented symptomatic paroxysmal atrial fibrillation that did not respond to treatment with at least 1 class 1 or III antiarrhythmic medication.
  • Have been recommended for ablation procedure or recently underwent CB ablation procedure.

This is a partial list of inclusion and exclusion criteria. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Heart and Vascular Conditions
Contact Email: 
Contact Phone: 
(312) 942-1604
Contact Name: 
Samia Majid